LinkMed’s portfolio company receives order from Siemens AG for DIGNITY Carrier

NewsGuard 100/100 Score

“We are very excited about this strategic order from the Siemen’s PET division. We foresee from now on a new market segment for accurate in vivo dose verification after high energy radiotherapy, where ONCOlog Medical can become one of the leading companies”

LinkMed’s portfolio company has received an order from Siemens AG, Health Care Sector, Germany for its patient transportation solution, DIGNITY™ Carrier, for setting up patients for PET/CT imaging for special applications.

The first installation with the unique solution of smooth transportation of patients, from set up and/or treatment rooms to PET/CT room, will be done at the Particle Therapy Centre at the University of Heidelberg in Germany during spring 2010. The order includes a special adaption of the DIGNITY™ Carrier to allow smooth docking to the Siemens PET/CT.

In particle therapy PET imaging is a non-invasive way of in vivo verification of the dose delivered to the target volume, by monitoring induced radiation from positron emitting isotopes such as 11C and 15O.

The degradation of activity (half-life for 11C is twenty minutes and for 15O two minutes) requires that the irradiated patient must be moved for PET imaging in a very short time. This has up till now been very difficult without changing the patient´s geometrical set up conditions.

With the ONCOlog Medical DIGNITY™ Carrier, the irradiated patient can be transported in treatment position to PET imaging fast and smoothly.

“We are very excited about this strategic order from the Siemen’s PET division. We foresee from now on a new market segment for accurate in vivo dose verification after high energy radiotherapy, where ONCOlog Medical can become one of the leading companies”, says Hans Dahlin, CEO of ONCOlog Medical.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough in CRISPR delivery promises safer gene editing